Outcome Reporting in Industry-Sponsored Trials of Gabapentin for Off-Label Use
New England Journal of MedicinePublished 11 November 2009
S. Swaroop Vedula, Lisa Bero, Roberta W. Scherer, Kay Dickersin
Citations362
SJR quartileQ1
SJR score19.08
SNIP13.47
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Examination of reporting practices for trials of gabapentin funded by Pfizer and Warner-Lambert's subsidiary, Parke-Davis for off-label indications found selective outcome reporting threatens the validity of evidence for the effectiveness of off- label interventions.
Abstract
We identified selective outcome reporting for trials of off-label use of gabapentin. This practice threatens the validity of evidence for the effectiveness of off-label interventions.
Keywords
MedicineEconomics, Econometrics and FinancePharmacology, Toxicology and Pharmaceutics
New England Journal of MedicineEffect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
4,666 Citations2007Steven E. Nissen, Kathy Wolski
Patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for type 2 diabetes mellitus as well as the availability of outcome data for myocardial infarction and death from cardiovascular causes.
New England Journal of MedicineSelective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy
2,426 Citations2008Erick H. Turner, Annette M. Matthews +3 more
A systematic literature search found that among 74 FDA-registered studies, 31%, accounting for 3449 study participants, were not published, and the increase in effect size ranged from 11 to 69% for individual drugs and was 32% overall.
Fundamentals of Clinical Trials
2,205 Citations2015Lawrence M. Friedman, Curt D. Furberg +3 more
Publication Bias in Meta‐Analysis
2,197 Citations2005Hannah R. Rothstein, Alex J. Sutton +1 more
This work states that within Conventional Publication Bias: Other Determinants of Data Suppression (Scott D. Halpern and Jesse A. Berlin), differentiating Biases from Genuine Heterogeneity: Distinguishing Artifactual from Substantive Effects (John P.A. Ioannidis).
BMJPharmaceutical industry sponsorship and research outcome and quality: systematic review
2,163 Citations2003Joel Lexchin, Lisa A Bero +2 more
Investigating whether funding of drug studies by the pharmaceutical industry is associated with outcomes that are favourable to the funder and whether the methods of trials funded by pharmaceutical companies differ from the methods in trials with other sources of support found systematic bias favours products which are made by the company funding the research.
JAMAEmpirical Evidence for Selective Reporting of Outcomes in Randomized Trials
1,806 Citations2004An‐Wen Chan, Asbjørn Hróbjartsson +3 more
The reporting of trial outcomes is not only frequently incomplete but also biased and inconsistent with protocols and Published articles, as well as reviews that incorporate them, may therefore be unreliable and overestimate the benefits of an intervention.
JAMAGabapentin for the Symptomatic Treatment of Painful Neuropathy in Patients With Diabetes Mellitus<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
1,527 Citations1998Miroslav Bačkonja
Gabapentin monotherapy appears to be efficacious for the treatment of pain and sleep interference associated with diabetic peripheral neuropathy and exhibits positive effects on mood and quality of life.
JAMAFactors Influencing Publication of Research Results
853 Citations1992Kay Dickersin
There was evidence of publication bias in that for both institutional review boards there was an association between results reported to be significant and publication and contrary to popular opinion, publication bias originates primarily with investigators, not journal editors.
BMJEvidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications
639 Citations2003Hans Melander, Jane Ahlqvist-Rastad +2 more
Any attempt to recommend a specific selective serotonin reuptake inhibitor from the publicly available data only is likely to be based on biased evidence.
JAMARegistering Clinical Trials
514 Citations2003Kay Dickersin
All stakeholders-investigators, research organizations and institutions, journal editors, lawmakers, consumers, and others-must act now, together and in their own domains, to ensure comprehensive registration of clinical trials.
The LancetThe uncertainty principle and industry-sponsored research
488 Citations2000Benjamin Djulbegović, M. Lacevic +6 more
The quality of 136 published randomised trials that focused on one disease category (multiple myeloma) and adherence to the uncertainty principle were examined, and the reported bias in research sponsored by the pharmaceutical industry may be a consequence of violations of that principle.
Canadian Medical Association JournalOutcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research
446 Citations2004A.-W. Chan
Whether outcome reporting bias would be present in a cohort of government-funded trials subjected to rigorous peer review and whether primary outcomes specified in trial protocols were compared with those reported in publications is compared.
PainGabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial
430 Citations2002Mick Serpell
This study shows that gabapentin reduces pain and improves some quality‐of‐life measures in patients with a wide range of neuropathic pain syndromes.
Clinical TherapeuticsGabapentin dosing for neuropathic pain: Evidence from randomized, placebo-controlled clinical trials
420 Citations2003Miroslav Bačkonja, Robert Glanzman
JAMAPublication Bias in Editorial Decision Making
391 Citations2002Carin M Olson
Whether submitted manuscripts that report results of controlled trials are more likely to be published if they report positive results and whether publication bias occurs once manuscripts have been submitted to a medical journal is assessed.
Headache The Journal of Head and Face PainEfficacy of Gabapentin in Migraine Prophylaxis
341 Citations2001Ninan T. Mathew, Alan M. Rapoport +6 more
The objective is to compare gabapentin with placebo for use as a prophylactic agent in patients with migraine (with or without aura).
Annals of Internal MedicineNarrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents
333 Citations2006Michael A. Steinman, Lisa Bero +2 more
How marketing strategies and tactics for gabapentin were developed and used in the mid- and late 1990s are described, focusing on how certain groups of physicians were targeted as recipients of and vehicles for promotion.
PLoS MedicineReporting Bias in Drug Trials Submitted to the Food and Drug Administration: Review of Publication and Presentation
322 Citations2008Kristin L. Rising, Peter Bacchetti +1 more
The publication rate of efficacy trials submitted to the Food and Drug Administration in approved New Drug Applications (NDAs) is determined and the trial characteristics as reported by the FDA with those reported in publications are compared.
Bipolar DisordersGabapentin in bipolar disorder: a placebo‐controlled trial of adjunctive therapy1
317 Citations2000Atul C. Pande, Jerri G. Crockatt +4 more
The findings of this study did not demonstrate that gabapentin is an effective adjunctive treatment when administered to outpatients with bipolar disorder.
Journal of Clinical OncologyGabapentin for Neuropathic Cancer Pain: A Randomized Controlled Trial From the Gabapentin Cancer Pain Study Group
313 Citations2004Augusto Caraceni, Ernesto Zecca +10 more
Gabapentin is effective in improving analgesia in patients with neuropathic cancer pain already treated with opioids, and analysis of covariance on the intent-to-treat population showed a significant difference.
PubMedNIH clinical trials and publication bias.
298 Citations1993Kay Dickersin, Yuan‐I Min
Even when the overall publication rate is high, such as for trials funded by the NIH, publication bias remains a significant problem and more reliable systems for maintaining information about initiated studies are needed.
Annals of Internal MedicineClinical Trial Registration: A Statement from the International Committee of Medical Journal Editors
275 Citations2004Catherine De Angelis, Jeffrey M. Drazen +11 more
The International Committee of Medical Journal Editors (ICMJE) proposes comprehensive trials registration as a solution to the problem of selective awareness and announces that all 11 ICMJE member journals will adopt a trials-registration policy to promote this goal.
BMJPrinciples for international registration of protocol information and results from human trials of health related interventions: Ottawa statement (part 1)
239 Citations2005Karmela Krleža-Jerić, An‐Wen Chan +4 more
An open meeting on 4 October 2004 in Ottawa, Canada, to foster international consensus on trial registration aims to establish internationally recognised principles for registration and highlights and discusses some of the key principles.
Cochrane Database of Systematic ReviewsGabapentin for acute and chronic pain
231 Citations2011Philip J Wiffen, Henry J McQuay +2 more
Evidence is shown that gabapentin is effective in neuropathic pain, and there is limited evidence to show that gabsentin is ineffective in acute pain.
PLoS MedicinePublication of Clinical Trials Supporting Successful New Drug Applications: A Literature Analysis
217 Citations2008Kirby Lee, Peter Bacchetti +1 more
The proportion of trials submitted to the FDA in support of newly approved drugs that are published in biomedical journals that a typical clinician, consumer, or policy maker living in the US would reasonably search is determined.
Journal of Neurology Neurosurgery & PsychiatryGabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial
207 Citations1999Kenneth C. Gorson, Céline Schott +3 more
A randomised, double blind, placebo controlled trial to study the effect of low dose gabapentin in patients with painful diabetic neuropathy, which suggests it ameliorates pain associated with neuropathy and other neurological conditions with few side effects.
JAMAFactors influencing publication of research results. Follow-up of applications submitted to two institutional review boards
194 Citations1992Kay Dickersin
JAMAReporting Mortality Findings in Trials of Rofecoxib for Alzheimer Disease or Cognitive Impairment
173 Citations2008Bruce M. Psaty, Richard A. Kronmal
The findings from this case study suggest that additional protections for human research participants, including new approaches for the conduct, oversight, and reporting of industry-sponsored trials, are necessary.
Annals of Internal MedicineThe ADVANTAGE Seeding Trial: A Review of Internal Documents
136 Citations2008Kevin P. Hill, Joseph S. Ross +2 more
A view of the planning, implementation, and publication of a seeding trial from the pharmaceutical company's perspective is offered, as well as a review of the documents related to the ADVANTAGE clinical trial.
PainGabapentin in traumatic nerve injury pain: A randomized, double-blind, placebo-controlled, cross-over, multi-center study
135 Citations2008Torsten Gordh, Audun Stubhaug +7 more
There was no statistically significant difference between the treatments for the primary outcome efficacy variable, but gabapentin provided significantly better pain relief compared with placebo.
Journal of Pain and Symptom ManagementGabapentin vs. Amitriptyline in Painful Diabetic Neuropathy
131 Citations2000Carlo Dallocchio, Carlo Buffa +2 more
Gabapentin produced greater improvements in pain and paresthesia associated with diabetic neuropathy and was better tolerated than amitriptyline, and further controlled trials are needed to confirm these preliminary results.
The LancetWHO facilitates international collaboration in setting standards for clinical trial registration
101 Citations2005A Metin Gülmezoglu, Tikki Pang +2 more
International Journal of Risk & Safety in MedicineClinical trials and drug promotion: Selective reporting of study 329
99 Citations2008Jon Jureidini, Leemon B. McHenry +1 more
Documents obtained during litigation reveal that study 329 of paroxetine was negative for efficacy on all 8 protocol specified outcomes and positive for harm.
NeurologyTreatment of chronic inflammatory demyelinating polyneuropathy with interferon-α 2a
90 Citations1998Kenneth C. Gorson, Allan H. Ropper +4 more
It is concluded that IFN-alpha may be effective in some patients with CIDP who relapse or fail to respond to conventional immunomodulating therapy.
The Journal of Clinical PsychiatryA Double-Blind, Randomized, Placebo-Controlled, Prophylaxis Study of Adjunctive Gabapentin for Bipolar Disorder
89 Citations2006Eduard Vieta, José Manuel Goikolea +6 more
This small, randomized clinical trial comparing the prophylactic efficacy of adjunctive gabapentin to placebo suggests that, despite lack of acute efficacy, treatment with gabAPentin might provide some benefit on the long-term outcome of bipolar disorder.
PLoS Clinical TrialsWhen and How Can Endpoints Be Changed after Initiation of a Randomized Clinical Trial
75 Citations2007Scott Evans
Some of the issues and decision-making processes that should be considered when evaluating whether to make changes to endpoints are discussed, and the documentation and reporting of clinical trials that have revised end points are discussed.
Bipolar DisordersGabapentin augmentation therapy in bipolar depression
63 Citations2002Po W. Wang, Claudia Santosa +4 more
Open adjunctive Gabapentin added to stable doses of mood stabilizers or atypical antipsychotics was effective and well tolerated in patients with mild to moderate bipolar depression.
JAMAFDA Guidance on Off-Label Promotion and the State of the Literature From Sponsors
25 Citations2008Bruce M. Psaty
Although peer-reviewed literature serves as the gold standard for evidence-based medicine, there are major limitations in relying on sponsordistributed literature to regulate off-label use, including the selective publication of studies, the systematic manipulation of the literature, the absence from the literature of critical data necessary for evaluating off- label use, and the potential for undermining the NDA review process.
The British Journal of DiabetesGabapentin for the treatment of painful diabetic neuropathy: dosing to achieve optimal clinical response
12 Citations2004Francisco J. Gómez‐Pérez, Armando Perez-Monteverde +8 more
The objective is to determine whether gabapentin titrated to achieve clinical effect provides superior efficacy to a commonly prescribed fixed-dose (900—3,600 mg/day) and to establish a protocol for evaluating this effect.
Issues in Data Analysis
10 Citations2010Lawrence M. Friedman, Curt D. Furberg +1 more
The analysis of data obtained from a clinical trial represents the outcome of the planning and implementation already described and must be done with as much care and concern as any of the design or data-gathering aspects.